Community-acquired CTX-M-15-type ESBL-producing Escherichia coli meningitis: a case report and literature review.

In this report, a case of community-acquired acute bacterial meningitis (CA-ABM) caused by CTX-M-15-producing Escherichia coli in an elderly male patient was presented in the light of literature. Cultures of cerebrospinal fluid, blood, ear discharge, and stool samples yielded CTX-M-15-producing E. coli in-vitro, which was resistant to the extended-spectrum cephalosporins and ciprofloxacin and susceptible to imipenem, meropenem and amikacin. Meningitis was treated with parenteral meropenem plus parenteral and intraventricular amikacin administration. Since bacterial meningitis is a life-threatening infection, empiric antibiotic therapy with carbapenem can be started before the culture results are obtained, mainly in areas where the ESBL epidemiology is well known.

[1]  É. Senneville,et al.  First Initial community-acquired meningitis due to extended-spectrum beta-lactamase producing Escherichia coli complicated with multiple aortic mycotic aneurysms , 2012, Annals of Clinical Microbiology and Antimicrobials.

[2]  E. Denamur,et al.  Meningitis Caused by Escherichia coli Producing TEM-52 Extended-Spectrum β-Lactamase within an Extensive Outbreak in a Neonatal Ward: Epidemiological Investigation and Characterization of the Strain , 2010, Journal of Clinical Microbiology.

[3]  A. Pitondo-Silva,et al.  Determinants of beta-lactam resistance in meningitis-causing Enterobacteriaceae in Brazil. , 2010, Canadian journal of microbiology.

[4]  Z. Yuluğkural,et al.  CTX-M type extended spectrum beta-lactamases in Escherichia coli isolates from community acquired upper urinary tract infections at a university in the European part of Turkey. , 2010, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[5]  Ş. Çolakoğlu,et al.  Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  P. Hawkey,et al.  The changing epidemiology of resistance. , 2009, The Journal of antimicrobial chemotherapy.

[7]  J. Lemeland,et al.  CTX-M-15-producing Escherichia coli in fatal neonatal meningitis: failure of empirical chemotherapy. , 2008, The Journal of antimicrobial chemotherapy.

[8]  J. Rodríguez-Baño,et al.  Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. , 2008, The Journal of antimicrobial chemotherapy.

[9]  J. Lavigne,et al.  Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. , 2008, The Journal of antimicrobial chemotherapy.

[10]  A. Carattoli,et al.  Dissemination of CTX-M-15 β-Lactamase Genes Carried on Inc FI and FII Plasmids among Clinical Isolates of Escherichia coli in a University Hospital in Istanbul, Turkey , 2008, Journal of Clinical Microbiology.

[11]  Y. Carmeli,et al.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. , 2007, The Journal of antimicrobial chemotherapy.

[12]  M. Karvaj,et al.  Gram-negative bacillary community acquired meningitis is not a rare entity in last two decades. , 2007, Neuro endocrinology letters.

[13]  I. Petersen,et al.  Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. , 2007, The Journal of infection.

[14]  E. Ferreira,et al.  CTX-M-3 and CTX-M-15 Extended-Spectrum β-Lactamases in Isolates of Escherichia coli from a Hospital in Algiers, Algeria , 2006, Journal of Clinical Microbiology.

[15]  K. Laupland,et al.  Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. , 2005, The Journal of antimicrobial chemotherapy.

[16]  A. Arısoy,et al.  An outbreak of SHV-5 producing Klebsiella pneumoniae in a neonatal intensive care unit; meropenem failed to avoid fecal colonization. , 2005, The new microbiologica.

[17]  Allan R Tunkel,et al.  Practice guidelines for the management of bacterial meningitis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  S. Zanetti,et al.  PER-1 type beta-lactamase production in Acinetobacter baumannii is related to cell adhesion. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[19]  V. Caviness,et al.  Acute bacterial meningitis in adults. A review of 493 episodes. , 1993, The New England journal of medicine.

[20]  K. Chokephaibulkit,et al.  Septicemia, meningitis, and skull osteomyelitis complicating infected cephalhematoma caused by ESBL-producing Escherichia coli. , 2011, The Southeast Asian journal of tropical medicine and public health.

[21]  A. Shorr,et al.  Nosocomial bacterial meningitis. , 2010, The New England journal of medicine.

[22]  G. Rossolini,et al.  The spread of CTX-M-type extended-spectrum beta-lactamases. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[23]  G. Rossolini,et al.  The spread of CTX-M-type extended-spectrum β-lactamases , 2008 .